For the quarter ended March 2025, Hologic (HOLX) reported revenue of $1.01 billion, down 1.2% over the same period last year. EPS came in at $1.03, compared to $1.03 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1 billion, representing a surprise of +0.34%. The company delivered an EPS surprise of +0.98%, with the consensus EPS estimate being $1.02.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Hologic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Diagnostics- Cytology and perinatal: $118.50 million compared to the $119.94 million average estimate based on three analysts. The reported number represents a change of -1.7% year over year.
- Revenues- Diagnostics- Molecular diagnostics: $326 million compared to the $328.58 million average estimate based on three analysts. The reported number represents a change of +1% year over year.
- Revenues- Diagnostics- Blood screening: $9.10 million versus the three-analyst average estimate of $4.99 million. The reported number represents a year-over-year change of +31.9%.
- Revenues- Breast health- Breast imaging: $271.90 million compared to the $282.58 million average estimate based on three analysts. The reported number represents a change of -11.4% year over year.
- Revenues- Skeletal health: $33 million compared to the $18 million average estimate based on three analysts. The reported number represents a change of +21.8% year over year.
- Revenues- Total Breast health: $356.20 million compared to the $369.50 million average estimate based on three analysts. The reported number represents a change of -7.4% year over year.
- Revenues- Total Diagnostics: $453.60 million versus the three-analyst average estimate of $453.52 million. The reported number represents a year-over-year change of +0.8%.
- Revenues- GYN surgical: $162.50 million versus $161.11 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.2% change.
- Revenues- Breast health- Interventional breast solutions: $84.30 million versus the three-analyst average estimate of $86.91 million. The reported number represents a year-over-year change of +8.2%.
View all Key Company Metrics for Hologic here>>>
Shares of Hologic have returned -3.9% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hologic, Inc. (HOLX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
